Ipsen reported yet another strong quarter. The revenue for Q3 FY16 (at CER unless specified otherwise) increased by 12.2% (vs Q2 16: +14.5%), fuelled by strong growth in the speciality care ‘SC’ segment (+17.8% vs Q2 16: +18.6%; accounts for c.82% of Q3 16 sales). Within the segment, Somatuline was the largest growth contributor (+34.1% vs Q2 16: +37.4%; accounts for c.35% of Q3 16 sales), and once again drove the robust volume growth and favourable pricing trend in the North Amer
12 Jan 2017
Solid financial performance; new mid-term growth engine instilled by the CEO
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Solid financial performance; new mid-term growth engine instilled by the CEO
Ipsen SA (IPN:WBO) | 0 0 5.0% | Mkt Cap: 10,144m
- Published:
12 Jan 2017 -
Author:
Nishant Choudhary -
Pages:
4
Ipsen reported yet another strong quarter. The revenue for Q3 FY16 (at CER unless specified otherwise) increased by 12.2% (vs Q2 16: +14.5%), fuelled by strong growth in the speciality care ‘SC’ segment (+17.8% vs Q2 16: +18.6%; accounts for c.82% of Q3 16 sales). Within the segment, Somatuline was the largest growth contributor (+34.1% vs Q2 16: +37.4%; accounts for c.35% of Q3 16 sales), and once again drove the robust volume growth and favourable pricing trend in the North Amer